Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
THE LONG CON
By Michael Lawrence Langan MD
Ya gotta spend money to make money, am I right?
The payoffs required are enormous, but once they get in, they make tons of money, and jacking the price of drugs to boot.
President Trump promised that he would take care of that and make a deal to roll back drug prices, but then he met with […]
***
***
The long con: Big Pharma Quietly Enlists Leading Professors to Justify $1,000-Per-Day Drugs — Later On
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care
***
Share this:
Filed under: Drugs and Pharma | Tagged: Big Pharma Quietly Enlists Leading Professors, Michael Lawrence Langan MD, Professors Justify Drugs — |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Top Five Prescription Drugs by Revenue in 2016
1. Humira (AbbVie) $16.078 billion
2. Harvoni (Gilead Sciences) $9.081 billion
3. Enbrel (Amgen and Pfizer) $8.874 bllion
4. Rituxan (Roche [Genentech] and Biogen) $8.583 billion
5. Remicade (Johnson & Johnson and Merck) $7.829 billion
Source: Genetic Engineering & Biotechnology News
LikeLike
77% Say That Prescription Drug Prices Are Unreasonable
EP Vantage recently published an article on prescription drug pricing trends and perceptions. Here are some key findings from the report:
• 77% of people surveyed in 2016 believed that the price of drugs was unreasonable.
• In 2008, 79% believed that the price of drugs was unreasonable.
• More than 70% of people say it is very or somewhat easy to afford prescriptions.
• Copayments for speciality drugs in separate tiers average $89 per prescription.
• Four-tier cost-sharing plans are in place at nearly a third of employers.
• A patent cliff in 2019 puts $41bn at risk, but $19bn in sales is expected be lost.
Source: EP Vantage, August 21, 2017
LikeLike
Specialty Meds: The Ten Most Expensive Specialty Drugs
1. Glybera (alipogene tiparvovec)
2. Ravicti (glycerol phenylbutyrate)
3. Brineura (cerliponase alfa)
4. Carbaglu (carglumic acid)
5. Lumizyme (alglucosidase alfa)
6. Actimmune (interferon gamma-1b)
7. Soliris (eculizumab)
8. Folotyn (pralatrexate)
9. Demser (metyrosine)
10. Ilaris (canakinumab)
Source: Drugs.com
LikeLike